LT-002-158

N/A

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameLT-002-158
Drug Alias NameLT-002-158LT002158LT-002 (Leadingtac)
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionInterleukin-1 receptor-associated kinase 4 degraders
TargetsInterleukin-1 receptor-associated kinase 4
Therapy Area/IndicationsAutoimmune DiseasesPsoriasisRosacea +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Leadingtac Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Leadingtac Pharmaceutical Co LtdLilac Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesPsoriasisRosacea +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A